Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raed Alroughani

Showing results (191-200 of 223) with videos related to

Pageof 23
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Pageof 23

Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Frontiers in Neurology|January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Pageof 23